Literature DB >> 16825494

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.

Joaquim Carreras1, Armando Lopez-Guillermo, Bridget C Fox, Lluis Colomo, Antonio Martinez, Giovanna Roncador, Emili Montserrat, Elias Campo, Alison H Banham.   

Abstract

The tumor microenvironment plays an important role in the biologic behavior of follicular lymphoma (FL), but the specific cell subsets involved in this regulation are unknown. To determine the impact of FOXP3-positive regulatory T cells (Tregs) in the progression and outcome of FL patients, we examined samples from 97 patients at diagnosis and 37 at first relapse with an anti-FOXP3 monoclonal antibody. Tregs were quantified using computerized image analysis. The median overall survival (OS) of the series was 9.9 years, and the FL International Prognostic Index (FLIPI) was prognostically significant. The median Treg percentage at diagnosis was 10.5%. Overall, 49 patients had more than 10% Tregs, 30 between 5% to 10%, and 19 less than 5%, with a 5-year OS of 80%, 74%, and 50%, respectively (P = .001). Patients with very low numbers of Tregs (< 5%) presented more frequently with refractory disease (P = .007). The prognostic significance of Treg numbers was independent of the FLIPI. Seven transformed diffuse large B-cell lymphomas (DLBCLs) had lower Treg percentages (mean: 3.3%) than FL grades 1,2 (mean: 12.1%) or 3 (mean: 9%) (P < .02). In conclusion, high Treg numbers predict improved survival of FL patients, while a marked reduction in Tregs is observed on transformation to DLBCL.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16825494     DOI: 10.1182/blood-2006-04-018218

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  159 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

Review 2.  Evaluation of current cancer immunotherapy: hemato-oncology.

Authors:  Christopher S Hourigan; Hyam I Levitsky
Journal:  Cancer J       Date:  2011 Sep-Oct       Impact factor: 3.360

Review 3.  The host-tumor interface in B-cell non-Hodgkin lymphoma: a new world to investigate.

Authors:  Nicolas Rachinel; Gilles Salles
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

4.  JPEG2000 for automated quantification of immunohistochemically stained cell nuclei: a comparative study with standard JPEG format.

Authors:  Marylène Lejeune; Carlos López; Ramón Bosch; Anna Korzyńska; Maria-Teresa Salvadó; Marcial García-Rojo; Urszula Neuman; Łukasz Witkowski; Jordi Baucells; Joaquín Jaén
Journal:  Virchows Arch       Date:  2010-11-18       Impact factor: 4.064

5.  Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients.

Authors:  Mehdi Dehghani; Shokouh Sharifpour; Zahra Amirghofran; Hamid Reza Zare
Journal:  Med Oncol       Date:  2012-02-04       Impact factor: 3.064

6.  Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.

Authors:  Chun Chao; Lanfang Xu; Michael J Silverberg; Otoniel Martínez-Maza; Lie-Hong Chen; Brandon Castor; Donald I Abrams; Hongbin D Zha; Reina Haque; Jonathan Said
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

7.  Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma.

Authors:  Kui Shin Voo; Myriam Foglietta; Elena Percivalle; Fuliang Chu; Durga Nattamai; Megan Harline; Seung-Tae Lee; Laura Bover; Heather Y Lin; Veerabhadran Baladandayuthapani; David Delgado; Amber Luong; R Eric Davis; Larry W Kwak; Yong-Jun Liu; Sattva S Neelapu
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Harnessing the immune system to treat cancer.

Authors:  Nina Bhardwaj
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 10.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.